Precigen has been granted a patent for polynucleotides encoding ligand-inducible gene switch polypeptides, allowing for the modulation of gene expression in host cells. The patent also covers a method for integrating heterologous genes into peripheral blood mononuclear cells using specific recombinase enzymes. GlobalData’s report on Precigen gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Precigen, Cancer treatment biomarkers was a key innovation area identified from patents. Precigen's grant share as of April 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Method for integrating genes into pbmc genome
A recently granted patent (Publication Number: US11946054B2) discloses a method for integrating heterologous genes into the genome of peripheral blood mononuclear cells (PBMCs). The method involves delivering a non-naturally occurring polynucleotide containing an AttP or AttB recombination sequence along with the heterologous gene(s), and a polynucleotide encoding a serine recombinase such as SF370, SPßc2, Bxb1, A118, or fRv1. The delivery of these polynucleotides can be achieved through various methods like transfection, transformation, nucleofection, or transduction, using techniques like calcium phosphate precipitation, lipofection, particle bombardment, or microinjection.
Furthermore, the patent claims encompass the inclusion of cytokines, cell tags, and fusion proteins in the non-naturally occurring polynucleotide, along with chimeric antigen receptors capable of binding to specific targets like CD19, EGFRvIII, CD33, ROR1, and MUC-16. The chimeric antigen receptors described in the claims have specific amino acid sequences with high identity to certain SEQ ID NOs, allowing for precise targeting and integration into PBMCs. This method opens up possibilities for genetic modifications in immune cells, particularly T cells and NK cells, for potential therapeutic applications in areas like cancer immunotherapy and targeted antigen recognition.
To know more about GlobalData’s detailed insights on Precigen, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.